Michael Grant

118 posts

Michael Grant

Michael Grant

@MJGrantMD

med onc/ hematologist at @yalecancer | thoracic ca. | asst. professor @yalemed | alum @imresidencyduke, @yalehemonc

New Haven, CT Katılım Aralık 2017
466 Takip Edilen345 Takipçiler
Michael Grant retweetledi
Alessandro Di Federico
Alessandro Di Federico@DiFedericoMD·
A brief recap of our FRONT-BRAF study, retrospectively comparing immunotherapy +/- chemotherapy to BRAF+MEK inhibitors for the first-line treatment of patients with stage IV, BRAF V600E-mutated NSCLC thelancet.com/journals/lanon… @BRicciutiMD @MDAndersonNews @MSKCancerCenter
Dana-Farber News@DanaFarberNews

A study in @TheLancetOncol, @danafarber researchers, led by @BRicciutiMD, suggests immunotherapy may be a better first treatment for a subset of non-small cell lung cancer patients. @DFarberThoracic Read more: bit.ly/4jSqfWK

English
1
7
19
2.8K
Michael Grant retweetledi
Gavitt Woodard
Gavitt Woodard@GavittWoodard·
Thanks @JTOonline for the opportunity to comment on this important topic. Strong data support 🫁 screening in smokers but I don't think we are ready to expand criteria to low-risk patients without more data on their survival benefit. More thoughts here: authors.elsevier.com/a/1jYFE_ZOPrsh…
JTO & JTO CRR@JTOonline

High-quality #LungCancer screening has a favorable net-benefit in early detection, thus better outcomes. But screening low-risk individuals like those with neither family histories, nor smoking histories may not have a benefit at all. Read More: bit.ly/LDCTScreening #LCSM

English
2
4
10
1.9K
Michael Grant retweetledi
Talal El Zarif, MD
Talal El Zarif, MD@TalalZarif1·
Enjoyed sharing our work on ERBB2 mutations in Lung Cancer with a Merit Award from @ConquerCancerFd! Thanks to @StockhammerPaul for spearheading this effort, @MJGrantMD @politikaterina #SarahGoldberg for the immense mentorship and to @TradIMYale for their support! #ASCO24
Karl Semaan, MD, MSc@KarlSemaan

Here is @TalalZarif1 eloquently discussing his merit-award receiving poster on ERBB2 mutations in Lung Cancer! @YaleIMed @YaleMedPSTP @YaleCancer #ASCO24

English
3
7
41
4.2K
Eric K. Singhi, MD
Eric K. Singhi, MD@lungoncdoc·
Y’all—I just received my first grant as faculty!! 🥹 Grateful to @LungsRLife for supporting our research dedicated to young patients with lung cancer, a cause I’m deeply passionate about. Thrilled to collaborate with surgical colleague & dear friend @maraantonoff! #lcsm
Eric K. Singhi, MD tweet mediaEric K. Singhi, MD tweet media
Austin, TX 🇺🇸 English
20
5
141
6.8K
Michael Grant retweetledi
Timil Patel, MD
Timil Patel, MD@timilpatel·
In NSCLC IO trials, the moderate link between ORR & PFS and OS necessitates thorough OS analyses, even if initial PFS results are not promising. This critical measure ensures potential survival benefits are not overlooked. @lobo_goulart @harpreet_md @FDAOncology
The Lancet Oncology@TheLancetOncol

NOW OF An FDA pooled analysis assess correlations of overall response rate and progression-free survival with overall survival in trials of immune checkpoint inhibitors for metastatic non-small-cell lung cancer (NSCLC). #LCSM thelancet.com/journals/lanon…

English
1
3
8
1.7K
Michael Grant retweetledi
Eric K. Singhi, MD
Eric K. Singhi, MD@lungoncdoc·
“Approximately half of the patients who experience disease progression s/p definitive CCRT & IO per PACIFIC regimen have low-volume relapse or oligometastatic relapse & therefore are candidates for further potentially curative-intent ablative therapy.” @IASLC @OncoAlert #lcsm
IASLC@IASLC

Patients who experience disease recurrence after receiving the PACIFIC regimen may be candidates for further ablative treatments, according to a recent analysis. Read more in #ILCN: ilcn.org/patterns-of-fa… @Nikhil_YR #LCSM

English
0
4
13
3.3K
Michael Grant retweetledi
Paul Stockhammer
Paul Stockhammer@StockhammerPaul·
Excited to share our recent work now published in @JTOonline: 👉Pts with #EGFR mt NSCLC with co-mut in TP53 and another suppressor gene have ⬆️aggressive dz and ⬇️outcomes on TKIs. 👉These findings may help to identify pts for Tx strategies beyond Osi. jto.org/article/S1556-…
English
1
8
34
7K
Michael Grant retweetledi
Lilly Oncology Medical
Lilly Oncology Medical@LillyOncMed·
At #EHA2023 - Learn about the genomic evolution & resistance to a highly selective, non-covalent (reversible) BTK inhibitor in patients with CLL that were previously treated with a covalent BTK inhibitor (cBTKi). #leusm #lymsm See the details here: e.lilly/45ONFVC
English
0
5
22
277.8K
Michael Grant retweetledi
Amin Nassar, MD
Amin Nassar, MD@AminNassarMD·
So fortunate to share our @TheLancet preprint. This is proof-of-concept showing that unanswered clinical questions in rare diseases can be accomplished by global collaboration across tens of centers! TOOK A VILLAGE to answer this and hopefully more similar efforts to come.
Talal El Zarif, MD@TalalZarif1

1/10. After our oral presentation at #GU23, we are excited to share our Lancet preprint on ICIs for penile cancer! Work co-led w/ @AminNassarMD & supervised by @sonpavde @apolo_andrea. A global study from @GTumors! @AndreaNecchi @SpiessPhilippe @DrChoueiri papers.ssrn.com/sol3/papers.cf…

English
8
7
52
15.8K
Paul Stockhammer
Paul Stockhammer@StockhammerPaul·
Very honored to have received the Young Investigator Award at the spectacular @EGFRSummit 2022. Thank you to the @EGFRResisters, the organizers + mentors, and my amazing mentors @politikaterina and #SarahGoldberg for this exciting opportunity! @YaleIMed @YaleCancer @MarkDSiegel1
EGFR Resisters Research Summit@EGFRSummit

The Distinguished Young Investigator Research Award for the 2022 YI cohort goes to the amazing @StockhammerPaul from @YaleMed for his work on the outcomes of co-occurring alts in multi-tumor suppressor genes in EGFRm lung cancer! 🎉✨🙌 Congratulations!! #EGFRSummit22 #LCAM #LCSM

English
14
6
82
0
Michael Grant retweetledi
Qasim Hussaini, MD
Qasim Hussaini, MD@QasimHussainiMD·
Out today in @BloodAdvances, we show stark disparities in access to end-of-life care for individuals with hematologic malignancies living in Rural America Our findings and thoughts on this important, nuanced & policy-relevant topic below. We can do better bit.ly/3xUbyfx
Qasim Hussaini, MD tweet media
English
2
15
69
0

Keşfet

@BRicciutiMD @MDAndersonnews @MSKCancerCenter @ChristianRolfo @IASLC @JTOonline @ConquerCancerFd @StockhammerPaul